Amplification of the DNMT3B gene is observed in breast cancer cells and has been implicated in resistance to DNA-demethylating therapeutics, e.g., 5-azacytidine (brand name Vidaza®), decitabine, and SGI-1027 [107]. This evidence concerns the gene DNMT3B and breast carcinoma.